<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">tau-therapeutics-pipeline</th>
</tr>
<tr>
<td class="label">Class</td>
<td>Representative Programs</td>
</tr>
<tr>
<td class="label">Passive antibodies</td>
<td>[Semorinemab](/entities/semorinemab), Tilavonemab, Bepranemab, JNJ-63733657, E2814</td>
</tr>
<tr>
<td class="label">ASO tau-lowering</td>
<td>[BIIB080](/entities/biiib080) (MAPTRx), other MAPT ASO programs</td>
</tr>
<tr>
<td class="label">OGA inhibition</td>
<td>LY3372689, MK-8719 class concept</td>
</tr>
<tr>
<td class="label">Vaccines</td>
<td>AADvac1, ACI-35 lineage</td>
</tr>
<tr>
<td class="label">Aggregation inhibitors</td>
<td>LMTM and related chemistry</td>
</tr>
<tr>
<td class="label">Gene/proteostasis approaches</td>
<td>Splicing modulation, [autophagy](/entities/autophagy)/proteasome enhancement, targeted degradation concepts</td>
</tr>
<tr>
<td class="label">Dimension</td>
<td>What high score means</td>
</tr>
<tr>
<td class="label">Mechanistic Fit To Tauopathy</td>
<td>Directly modifies pathogenic tau species central to disease</td>
</tr>
<tr>
<td class="label">Human Pharmacodynamic Evidence</td>
<td>Clear CNS target engagement in people</td>
</tr>
<tr>
<td class="label">Clinical Maturity</td>
<td>Controlled trial data in relevant indications</td>
</tr>
<tr>
<td class="label">PSP/CBS Relevance</td>
<td>Evidence or rationale for 4R
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">tau-therapeutics-pipeline</th>
</tr>
<tr>
<td class="label">Class</td>
<td>Representative Programs</td>
</tr>
<tr>
<td class="label">Passive antibodies</td>
<td>[Semorinemab](/entities/semorinemab), Tilavonemab, Bepranemab, JNJ-63733657, E2814</td>
</tr>
<tr>
<td class="label">ASO tau-lowering</td>
<td>[BIIB080](/entities/biiib080) (MAPTRx), other MAPT ASO programs</td>
</tr>
<tr>
<td class="label">OGA inhibition</td>
<td>LY3372689, MK-8719 class concept</td>
</tr>
<tr>
<td class="label">Vaccines</td>
<td>AADvac1, ACI-35 lineage</td>
</tr>
<tr>
<td class="label">Aggregation inhibitors</td>
<td>LMTM and related chemistry</td>
</tr>
<tr>
<td class="label">Gene/proteostasis approaches</td>
<td>Splicing modulation, [autophagy](/entities/autophagy)/proteasome enhancement, targeted degradation concepts</td>
</tr>
<tr>
<td class="label">Dimension</td>
<td>What high score means</td>
</tr>
<tr>
<td class="label">Mechanistic Fit To Tauopathy</td>
<td>Directly modifies pathogenic tau species central to disease</td>
</tr>
<tr>
<td class="label">Human Pharmacodynamic Evidence</td>
<td>Clear CNS target engagement in people</td>
</tr>
<tr>
<td class="label">Clinical Maturity</td>
<td>Controlled trial data in relevant indications</td>
</tr>
<tr>
<td class="label">PSP/CBS Relevance</td>
<td>Evidence or rationale for 4R tauopathies</td>
</tr>
<tr>
<td class="label">Safety/Implementability</td>
<td>Feasible chronic use and acceptable monitoring burden</td>
</tr>
<tr>
<td class="label">Biomarker Tractability</td>
<td>Can track response with PET/CSF/plasma readouts</td>
</tr>
<tr>
<td class="label">Modality</td>
<td>Mechanistic Fit</td>
</tr>
<tr>
<td class="label">ASO tau-lowering</td>
<td>9</td>
</tr>
<tr>
<td class="label">Passive anti-tau antibodies</td>
<td>8</td>
</tr>
<tr>
<td class="label">OGA inhibitors</td>
<td>8</td>
</tr>
<tr>
<td class="label">Active vaccines</td>
<td>7</td>
</tr>
<tr>
<td class="label">Aggregation inhibitors</td>
<td>7</td>
</tr>
<tr>
<td class="label">Gene/proteostasis emerging approaches</td>
<td>8</td>
</tr>
</table>
Tau-directed therapy is now a core strategy across [Alzheimer's disease](/diseases/alzheimers-disease), [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy), [corticobasal degeneration](/diseases/corticobasal-degeneration), and other primary tauopathies. The therapeutic premise is straightforward: prevent toxic tau species from forming, spreading, and disrupting neuronal function. The execution is difficult because tau biology is heterogeneous across diseases, with major differences in isoform composition, affected circuits, intracellular versus extracellular target accessibility, and trial endpoint sensitivity.[@wang2016][@lee2001][@mudher2017]
The modern pipeline has six major classes:
This page focuses on the near-to-mid-term translational pipeline and gives special attention to CBS/PSP relevance. Many large AD programs have generated critical negative data that are still highly informative for PSP/CBS development strategy.[@congdon2018][@boxer2014][@mullard2021]
Tau pathology tracks neuronal loss and clinical decline more closely than amyloid burden in symptomatic AD and directly defines primary tauopathies such as PSP and CBD. In PSP/CBS, the dominant pathology is often 4-repeat tau with region-specific vulnerability in brainstem, basal ganglia, and frontal-parietal networks.[@wang2016][@hglinger2017][@kovacs2017]
Multiple late-stage tau antibody programs failed to produce clear clinical benefit. The most likely reasons are a combination of target mismatch, treatment timing, suboptimal epitope selection, low CNS target engagement in the relevant compartment, and insensitive or noisy outcomes for slowly progressive syndromes.[@congdon2018][@boxer2014][@panza2019]
Negative trial outcomes should not be treated as global invalidation of tau targeting. They indicate that modality, epitope, disease stage, and biomarker-driven participant selection are decisive variables. Programs with stronger pharmacodynamic readouts and better disease-stage targeting remain rational to pursue.[@cummings2021][@mummery2023]
The rubric below scores intervention classes on a 0 to 10 scale across dimensions relevant to PSP/CBS translational decisions.
[Semorinemab](/entities/semorinemab) targeted extracellular tau with a mid-region epitope strategy. Despite compelling biological rationale, major AD trial programs did not deliver robust clinical efficacy in broad symptomatic populations. This result likely reflects both disease-stage complexity and uncertainty about whether extracellular tau neutralization alone is sufficient once intracellular aggregation and network degeneration are established.[@congdon2018][@panza2019]
For PSP/CBS planning, semorinemab-class outcomes argue for narrower enrichment and stronger biomarker-defined entry criteria rather than abandonment of antibody strategies. They also reinforce the need to match epitope design to dominant pathogenic species in 4R tauopathies.[@boxer2014][@cummings2021]
Tilavonemab was tested in PSP and failed to meet primary efficacy goals. This was a major setback because PSP is a canonical tauopathy and therefore seemed an ideal test bed. However, negative readout in one antibody program does not establish class failure. It does show that target biology, antibody distribution, and trial architecture require refinement, especially in fast-progressing brainstem syndromes where outcome noise is high.[@boxer2014][@jabbari2020]
These programs represent continued industry commitment to anti-tau antibodies with revised epitopes and development strategies. The translational lesson is that program selection should weigh not just target identity but demonstrated CNS target engagement, linkage to fluid/imaging biomarkers, and evidence that the selected epitope reflects disease-driving species in the intended population.[@cummings2021][@mummery2023]
E2814 and related initiatives increasingly emphasize combination logic and platform trial design, particularly in genetically enriched or biomarker-defined groups. This design philosophy may be more appropriate for tau-directed agents than traditional one-drug, one-endpoint paradigms, especially when treatment effects are likely to be modest and interaction-dependent.[@bateman2022]
ASO therapy is currently one of the strongest mechanistic strategies because it directly lowers MAPT transcript and downstream [tau protein](/proteins/tau) production. First-in-human results for [BIIB080](/entities/biiib080) demonstrated dose-dependent reductions in CSF total tau and phospho-tau species, giving one of the clearest human pharmacodynamic signals in the entire tau therapeutic field.[@mummery2023][@schrag2022]
This is strategically important for PSP/CBS because 4R tauopathies are fundamentally tau-load diseases, and upstream lowering could affect both soluble and aggregation-prone pools. Even if clinical efficacy remains unproven, pharmacodynamic confirmation substantially de-risks the mechanism relative to modalities that have not shown robust target engagement in humans.[@mummery2023]
ASOs currently require intrathecal administration, which is feasible but resource intensive. Key operational constraints include interval scheduling, lumbar procedure tolerance, long-term safety surveillance, and access inequities between major centers and community settings. These factors should be incorporated into practical treatment pathway planning, not treated as secondary issues.[@schrag2022][@bennett2019]
Given the lack of disease-modifying options in PSP/CBS, ASO approaches rank high for further development. Priority next steps include 4R-enriched cohorts, sensitive progression biomarkers, and trial endpoints that capture axial motor and frontal-executive domains more effectively than broad scales alone.[@hglinger2017][@golbe2007]
Tau phosphorylation state is dynamically regulated. Increasing tau O-GlcNAcylation by inhibiting O-GlcNAcase can reduce hyperphosphorylation pressure and potentially decrease aggregation propensity. This approach attempts to shift tau toward less pathological conformations rather than removing tau entirely.[@yuzwa2012][@selnick2019]
Programs such as LY3372689 and related OGA inhibitor classes moved into clinical development based on strong preclinical rationale and pharmacology. The central translational question is whether biochemical shifts in tau modifications will translate into measurable slowing of neurodegeneration in humans.[@yuzwa2012][@permanne2022]
OGA inhibition is attractive for chronic use because it is mechanistically targeted yet potentially less invasive than intrathecal therapies. For PSP/CBS, it may be particularly relevant in combination frameworks where upstream tau-lowering or immune-based clearance is paired with modulation of residual tau toxicity states.[@yuzwa2012]
AADvac1 generated meaningful immunogenicity in early work and represented a major proof that active tau immunotherapy is technically feasible in older adults. Later-stage efficacy outcomes were mixed and did not establish clear disease-modifying benefit in broad AD populations.[@novak2017][@novak2023]
From a pipeline perspective, AADvac1 still contributed critical data: epitope-focused active immunization can produce sustained antibody response, and vaccine platforms remain attractive for cost and dosing cadence if efficacy can be improved through better antigen design and population selection.[@novak2017]
ACI-35 programs advanced liposome-based phospho-tau immunization concepts. These efforts underscore a key strategic point: phospho-epitope specificity may matter as much as antibody titer. Vaccines may need tighter matching to disease-specific phospho-signatures and progression stage to achieve meaningful clinical impact.[@theunis2013][@novak2021]
Vaccines are operationally appealing for chronic disease management, but evidence in 4R tauopathies remains insufficient for high-confidence ranking. In the near term, vaccine participation is best framed as trial enrollment rather than established care.
Tau aggregation inhibitors such as methylthioninium derivatives were among the earliest disease-modifying tau strategies to reach large trials. Clinical outcomes have generally been inconsistent, with subgroup and design-dependent signals that did not convert into straightforward regulatory success.[@wischik2015][@gauthier2016]
Aggregation inhibition remains biologically plausible, especially for seed propagation control, but future success likely depends on tighter patient selection, early intervention windows, and integration with biomarker-defined pharmacodynamic goals. Standalone late-stage symptomatic use has not produced convincing results to date.[@wischik2015][@gauthier2016]
PSP/CBS pathology is strongly linked to 4R tau enrichment, making isoform-level strategies conceptually compelling. Experimental approaches that modulate MAPT exon 10 splicing could eventually align with disease-specific biology better than broad tau-neutralizing strategies.[@lee2001][@qian2014]
Because a substantial burden of pathogenic tau is intracellular, approaches that improve proteostasis, autophagy, lysosomal flux, or targeted degradation may be necessary complements to extracellular antibodies. This is an active preclinical and translational domain with high upside and high uncertainty.[@menzies2015][@silva2019]
The likely end-state is not one tau drug but layered intervention: production lowering, species modulation, and clearance enhancement with biomarker-guided adaptation. Trial design should therefore evolve toward adaptive combination frameworks rather than isolated single-agent bets.[@bateman2022][@cummings2019]
PSP and CBS differ from AD in lesion topography, functional decline profile, and available outcome tools. Trials must capture axial rigidity, oculomotor dysfunction, gait instability, bulbar decline, and frontal-executive deterioration with enough sensitivity to detect modest biologic effects.[@hglinger2017][@golbe2007][@armstrong2013]
Tau PET tracers are essential for regional burden tracking and target-population enrichment, though tracer performance differs across tau conformers and disease contexts. PSP/CBS tracer interpretation should be disease-specific rather than borrowed directly from AD assumptions.[@marqui2017][@brendel2021]
CSF total tau and phospho-tau species provide high-value pharmacodynamic readouts for tau-lowering and modification strategies. ASO development has reinforced the importance of serial CSF sampling for mechanism confirmation.[@mummery2023][@schrag2022]
Plasma p-tau assays, particularly [p-tau217](/biomarkers/p-tau-217) and p-tau181, improved scalability of monitoring and screening in AD-oriented programs. Their direct utility in PSP/CBS is evolving and requires disease-specific validation rather than simple transposition.[@janelidze2020][@palmqvist2020]
[NfL](/biomarkers/neurofilament-light-chain-nfl) remains a pragmatic degeneration marker for progression modeling and can complement tau-specific biomarkers. Combined use of NfL, tau PET, CSF tau species, and digital clinical measures is likely to provide the highest signal-to-noise profile for future trials.[@ashton2021]
Even effective tau therapies will only improve outcomes if they can be delivered repeatedly, safely, and equitably. Infusion centers, intrathecal procedure capacity, longitudinal monitoring infrastructure, and payer pathways are not peripheral details; they are core determinants of real-world impact.
Given rapid disability progression and absent disease-modifying standards, PSP/CBS patients may accept higher treatment burden than early AD populations if the probability of biologic effect is credible. This supports careful but proactive enrollment in high-quality tau therapeutic trials.
A practical update rule for this pipeline:
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate